|
1
|
Siegel R, Ma J, Zou Z and Jemal A: Cancer
statistics, 2014. CA Cancer J Clin. 64:9–29. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bokhman JV: Two pathogenetic types of
endometrial carcinoma. Gynecol Oncol. 15:10–17. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Creasman WT, Ali S, Mutch DG, Zaino RJ,
Powell MA, Mannel RS, Backes FJ, DiSilvestro PA, Argenta PA, Pearl
ML, et al: Surgical-pathological findings in type 1 and 2
endometrial cancer: An NRG Oncology/Gynecologic Oncology Group
study on GOG-210 protocol. Gynecol Oncol. 145:519–525. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
van Bakel H, Stout JM, Cote AG, Tallon CM,
Sharpe AG, Hughes TR and Page JE: The draft genome and
transcriptome of Cannabis sativa. Genome Biol. 12:R1022011.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Deiana S: Medical use of cannabis.
Cannabidiol: A new light for schizophrenia? Drug Test Anal.
5:46–51. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matsuda LA, Lolait SJ, Brownstein MJ,
Young AC and Bonner TI: Structure of a cannabinoid receptor and
functional expression of the cloned cDNA. Nature. 346:561–564.
1990. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Devane WA, Hanus L, Breuer A, Pertwee RG,
Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A and
Mechoulam R: Isolation and structure of a brain constituent that
binds to the cannabinoid receptor. Science. 258:1946–1949. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pertwee RG, Howlett AC, Abood ME,
Alexander SP, Di Marzo V, Elphick MR, Greasley PJ, Hansen HS, Kunos
G, Mackie K, et al: International Union of Basic and Clinical
Pharmacology. LXXIX. Cannabinoid receptors and their ligands:
Beyond CB1 and CB2. Pharmacol Rev.
62:588–631. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Mackie K: Distribution of cannabinoid
receptors in the central and peripheral nervous system. Handb Exp
Pharmaco. 299–325. 2005. View Article : Google Scholar
|
|
10
|
Velasco G, Sánchez C and Guzmán M: Towards
the use of cannabinoids as antitumour agents. Nat Rev Cancer.
12:436–444. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Caffarel MM, Sarrió D, Palacios J, Guzmán
M and Sánchez C: Delta9-tetrahydrocannabinol inhibits cell cycle
progression in human breast cancer cells through Cdc2 regulation.
Cancer Res. 66:6615–6621. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Casanova ML, Blázquez C, Martínez-Palacio
J, Villanueva C, Fernández-Aceñero MJ, Huffman JW, Jorcano JL and
Guzmán M: Inhibition of skin tumor growth and angiogenesis in vivo
by activation of cannabinoid receptors. J Clin Invest. 111:43–50.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Preet A, Qamri Z, Nasser MW, Prasad A,
Shilo K, Zou X, Groopman JE and Ganju RK: Cannabinoid receptors,
CB1 and CB2, as novel targets for inhibition of non-small cell lung
cancer growth and metastasis. Cancer Prev Res (Phila). 4:65–75.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Jiang R, Zhang C, Liu G, Gu R and Wu H:
MicroRNA-126 inhibits proliferation, migration, invasion, and EMT
in osteosarcoma by targeting ZEB1. J Cell Biochem. 118:3765–3774.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xie G, Ji A, Yuan Q, Jin Z, Yuan Y, Ren C,
Guo Z, Yao Q, Yang K, Lin X and Chen L: Tumour-initiating capacity
is independent of epithelial-mesenchymal transition status in
breast cancer cell lines. Br J Cancer. 110:2514–2523. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bauvois B: New facets of matrix
metalloproteinases MMP-2 and MMP-9 as cell surface transducers:
Outside-in signaling and relationship to tumor progression. Biochim
Biophys Acta. 1825:29–36. 2012.PubMed/NCBI
|
|
17
|
Burston JJ, Wiley JL, Craig AA, Selley DE
and Sim-Selley LJ: Regional enhancement of cannabinoid
CB₁ receptor desensitization in female adolescent rats
following repeated Delta-tetrahydrocannabinol exposure. Br J
Pharmacol. 161:103–112. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chang X, Bian Y, He Q, Yao J, Zhu J, Wu J,
Wang K and Duan T: Suppression of STAT3 signaling by
Δ9-Tetrahydrocannabinol (THC) induces trophoblast dysfunction. Cell
Physiol Biochem. 42:537–550. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shao R: Progesterone receptor isoforms A
and B: New insights into the mechanism of progesterone resistance
for the treatment of endometrial carcinoma. Ecancermedicalscience.
7:3812013.PubMed/NCBI
|
|
20
|
Hijiya N, Shibata T, Daa T, Hamanaka R,
Uchida T, Matsuura K, Tsukamoto Y, Nakada C, Iha H, Inomata M and
Moriyama M: Overexpression of cannabinoid receptor 1 in esophageal
squamous cell carcinoma is correlated with metastasis to lymph
nodes and distant organs, and poor prognosis. Pathol Int. 67:83–90.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Caffarel MM, Andradas C, Pérez-Gómez E,
Guzmán M and Sánchez C: Cannabinoids: A new hope for breast cancer
therapy? Cancer Treat Rev. 38:911–918. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ramer R, Heinemann K, Merkord J, Rohde H,
Salamon A, Linnebacher M and Hinz B: COX-2 and PPAR-γ confer
cannabidiol-induced apoptosis of human lung cancer cells. Mol
Cancer Ther. 12:69–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Salazar M, Carracedo A, Salanueva IJ,
Hernández-Tiedra S, Lorente M, Egia A, Vázquez P, Blázquez C,
Torres S, García S, et al: Cannabinoid action induces
autophagy-mediated cell death through stimulation of ER stress in
human glioma cells. J Clin Invest. 119:1359–1372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Guzmán M, Duarte MJ, Blázquez C, Ravina J,
Rosa MC, Galve-Roperh I, Sánchez C, Velasco G and González-Feria L:
A pilot clinical study of Delta9-tetrahydrocannabinol in patients
with recurrent glioblastoma multiforme. Br J Cancer. 95:197–203.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kramer JL: Medical marijuana for cancer.
CA Cancer J Clin. 65:109–122. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wilkie G, Sakr B and Rizack T: Medical
marijuana use in oncology: A review. JAMA Oncol. Mar 17–2016.(Epub
ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Araki K, Shimura T, Suzuki H, Tsutsumi S,
Wada W, Yajima T, Kobayahi T, Kubo N and Kuwano H: E/N-cadherin
switch mediates cancer progression via TGF-β-induced
epithelial-to-mesenchymal transition in extrahepatic
cholangiocarcinoma. Br J Cancer. 105:1885–1893. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grybos A and Bar J: The relationships
between the immunoexpression of KAI1, MMP-2, MMP-9 and steroid
receptors expression in endometrial cancer. Folia Histochem
Cytobiol. 52:187–194. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ghosh S, Preet A, Groopman JE and Ganju
RK: Cannabinoid receptor CB2 modulates the CXCL12/CXCR4-mediated
chemotaxis of T lymphocytes. Mol Immunol. 43:2169–2179. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
McAllister SD, Murase R, Christian RT, Lau
D, Zielinski AJ, Allison J, Almanza C, Pakdel A, Lee J, Limbad C,
et al: Pathways mediating the effects of cannabidiol on the
reduction of breast cancer cell proliferation, invasion, and
metastasis. Breast Cancer Res Treat. 129:37–47. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Adhikary S, Kocieda VP, Yen JH, Tuma RF
and Ganea D: Signaling through cannabinoid receptor 2 suppresses
murine dendritic cell migration by inhibiting matrix
metalloproteinase 9 expression. Blood. 120:3741–3749. 2012.
View Article : Google Scholar : PubMed/NCBI
|
